Accessibility Menu
Edwards Lifesciences logo

Edwards Lifesciences(NYSE) EW

Market Cap$49.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+6,137%
5 Year-24%
1 Year+7%
1 Month-6%
$87.00
+1.45%
+1.24Today
Edwards Lifesciences last closing stock price
MetricPriceDate
Last closeUSD 85.762026-07-29
Edwards Lifesciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.65%USD 84.372026-07-22
1 month-5.94%USD 91.182026-06-29
3 month+2.71%USD 83.502026-04-30
Year to date+0.6%USD 85.252025-12-31
1 year+6.57%USD 80.472025-07-29
3 year+2.41%USD 83.742023-07-28
5 year-23.61%USD 112.272021-07-30
Since inception+6,137.09%USD 1.382000-03-27

Edwards Lifesciences Financials at a Glance

Market Cap

$49.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.51B

Net Income (TTM)

$1.00B

EPS (TTM)

$1.69

P/E Ratio

50.89

Dividend

$0.00

Beta (Volatility)

0.85 (Low)

Price

$87.00

Volume

3,935,933

Open

$85.41

Previous Close

$86.92

Daily Range

$85.05 - $87.04

52-Week Range

$72.30 - $96.29

Estimated Earnings Date

Oct 29, 2026

EW News

Medical professional working at a computer terminal

Why Edwards Lifesciences Stock Plummeted Today

Eric VolkmanOct 26, 2023
man with diabetes checking blood sugar levels with wife

3 No-Brainer Medical Device Stocks to Buy Right Now

James HalleyApr 6, 2023
1 big red arrow going down over a stock chart.

Why Edwards Lifesciences Stock Crashed 16% Today

Rich SmithOct 28, 2022
investor sitting at a desk

3 Unstoppable Investments Everyone Needs in Their Portfolio

James BrumleyDec 31, 2021
GettyImages-167612910

Edwards Lifesciences Blows Past Q2 Earnings Estimates

Keith SpeightsJul 24, 2020
Judge signing order behind stethescope and gavel on a table

Abbott Laboratories and Edwards Lifesciences Settle Patent Fight

Eric VolkmanJul 13, 2020
GettyImages-800433994

Could Edwards Lifesciences Be a Millionaire-Maker Stock?

Alex CarchidiJun 27, 2020
GettyImages-638751964

Why Edwards Lifesciences Shares Rose 15.3% in April

Adria CiminoMay 4, 2020
Page 1

EW: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Edwards Lifesciences

Edwards Lifesciences makes heart valves and monitoring tools that help people with failing hearts. Their medical devices let doctors replace or repair damaged heart parts without always needing open-heart surgery. These technologies help patients recover faster and live longer lives.

The Heart of the Business

  • Transcatheter Aortic Valve Replacement: Heart valves put in place through a small tube while the heart still beats; accounted for 74% of net sales in 2025.
  • Transcatheter Mitral and Tricuspid Therapies: Repair and replacement tools for complex heart valve diseases; accounted for 9% of net sales in 2025.
  • Surgical Structural Heart: Advanced tissue heart valves used by surgeons in traditional operations; accounted for 17% of net sales in 2025.

Growth and Expansion

  • Sold the Critical Care product group to Becton, Dickinson and Company on September 3, 2025.
  • Launched the KONECT RESILIA aortic valved conduit in Europe in 2025.
  • Increased research and development spending by 2% in 2025 to focus on mitral, aortic, and tricuspid therapies.

What Makes Edwards Different?

The company maintains a global reach by selling products in approximately 100 countries through a direct sales force and independent distributors. It relies on a specialized manufacturing network in the United States, Singapore, Costa Rica, and Ireland to ensure a steady supply of heart valves.

A Look at the Numbers

  • Revenue reached $1.6 billion in Q4 2025, up 13.3% year-over-year.
  • Operating income was $370.3 million in Q4 2025, up 18.5% from Q4 2024.
  • Free cash flow hit $353.5 million in Q4 2025, up 299.4% from the same period in 2024.
  • Net income was $91.2 million in Q4 2025, down 76.3% year-over-year.

Bottom Line

Edwards has transitioned from a general medical device company into a specialized leader in structural heart innovation. By focusing on minimally invasive heart valve technology and tissue durability, the company has maintained its relevance in the competitive cardiovascular market.

AI Generated • Apr 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

16,000

CEO

Bernard J. Zovighian, MBA

Website

www.edwards.com

Headquarters

Irvine, CA 92614, US

EW Financials

Key Financial Metrics (TTM)

Gross Margin

77.98%

Operating Margin

28.09%

Net Income Margin

15.43%

Return on Equity

9.71%

Return on Capital

14.82%

Return on Assets

7.54%

Earnings Yield

1.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$49.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

575.80M

Volume

3.94M

Avg. Volume

5.11M

Financials (TTM)

Gross Profit

$5.08B

Operating Income

$1.83B

EBITDA

$1.54B

Operating Cash Flow

$1.36B

Capital Expenditure

-$269.10M

Free Cash Flow

$1.09B

Cash & ST Invst.

$3.67B

Total Debt

$702.90M

Edwards Lifesciences Performance Analysis

Edwards Lifesciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,382,400,0002.9%
20232023-12-31USD 5,010,000,000-6.9%
20242024-12-31USD 5,439,500,0008.6%
20252025-12-31USD 6,067,600,00011.5%
Edwards Lifesciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.4%
Q42025-12-311.1%
Q12026-03-315.0%
Q22026-06-305.6%
Edwards Lifesciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.442.4%
20232023-12-31USD 2.30-5.6%
20242024-12-31USD 1.46-36.6%
20252025-12-31USD 1.8124.0%
Edwards Lifesciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-10.7%
Q42025-12-31-68.0%
Q12026-03-31312.5%
Q22026-06-30-36.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.74B

+13.6%

Gross Profit

$1.35B

+13.5%

Gross Margin

77.56%

N/A

Market Cap

$49.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.09M

N/A

Employees

16,000

N/A

Net Income

$241.90M

-26.7%

EBITDA

$519.50M

+29.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.67B

-5.8%

Total Debt

$702.90M

+0.5%

Accounts Receivable

$973.00M

+29.4%

Inventory

$1.12B

+0.5%

Long Term Debt

$678.60M

+0.4%

Short Term Debt

$24.30M

+2.5%

Return on Assets

7.54%

N/A

Return on Invested Capital

15.36%

N/A

Free Cash Flow

-$21.10M

-109.4%

Operating Cash Flow

$43.80M

-84.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAHCardinal Health, Inc.
$227.07-0.89%
HLNHaleon plc
$10.11-1.65%
ARGXargenx SE
$872.58-1.13%
AAgilent Technologies, Inc.
$138.71-1.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About EW

What is the current price of Edwards Lifesciences?

Edwards Lifesciences is trading at $86.92 per share.

What is the 52-week range for Edwards Lifesciences?

Over the past 52 weeks, Edwards Lifesciences has traded between $72.30 and $96.29.

How much debt does Edwards Lifesciences have?

As of the most recent reporting period, Edwards Lifesciences reported total debt of $600.00M.

How much cash does Edwards Lifesciences have on hand?

Edwards Lifesciences reported $2.90B in cash and cash equivalents in its most recent financial results.

What is Edwards Lifesciences’s dividend yield?

Edwards Lifesciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services